The Brazilian health authorities began this Friday preliminary analyzes of the results of “Coronavac”, the candidate for the COVID-19 vaccine developed by the Chinese laboratory Sinovac and of which Brazil has already purchased 46 million doses.
The National Health Surveillance Agency (Anvisa) reported this Friday that received the first data packet with the results of the first experiments with this vaccine, carried out in the laboratory and with animals, to begin to analyze them and try to speed up their registration in case the tests with humans are successful.
According to Anvisa, the review of the first data is possible thanks to a mechanism that “allows you to verify the documents as they become available, but that does not mean that you have received the official request for registration of the vaccine.”
The regulatory agency of the Ministry of Health clarified that in this epreliminary cover of analysis will not yet rule on the vaccine registration But it will allow you to speed up the procedures for when you receive the request from the manufacturers for the immunizer to be registered in Brazil.
The documents were sent by the Brazilian laboratory Instituto Butantan, linked to the São Paulo governorate and which coordinates clinical trials of the vaccine in 13,060 volunteers in Brazil with the Chinese firm.
An agreement between Sinovac and the São Paulo government provides for the transfer of vaccine technology, which may be manufactured by the Butantan Institute when it is registered in Brazil.
At the moment, the São Paulo governorate has ordered 46 million doses of the vaccine to immunize the entire population of the richest and most populous state in Brazil as of December 15.
Brazil also analyzes AstraZeneca vaccine results
Anvisa had also started on Thursday the preliminary analysis of the candidate for a coronavirus vaccine developed by the company AstraZeneca and the University of Oxford, from which the Brazilian Ministry of Health acquired 100 million doses to start the immunization campaign when the medicine is registered.
Preliminary studies of both vaccines will focus on data collected in the early phases of the research, which only included laboratory and animal experiments.
“For now, Anvisa has the first data on the two vaccines, but it is important to clarify that there is no conclusion at this time on the quality, safety or efficacy of either of the two vaccines, which are still in their third testing phase (with volunteers), “explained the regulator.
“The objective of sending part of the data in advance is to allow as quickly as possible, within the scientific and protocol standards of Anvisa, the registration process of Coronavac, one of the most promising vaccines and which is in its last testing stage around the world, “said Sao Paulo Governor Joao Doria.
The governor of Sao Paulo hopes that, once approved by the Brazilian health authorities, the vaccination campaign with the initial 46 million doses begins next December 15 with a first phase in which health professionals in this state will be immunized.
Brazil is the second country with the most deaths in the world from COVID-19 after the United States, with 145,388 deaths, and the third with the most infections after the United States and India, with 4.88 million confirmed cases.
The Latin American giant was chosen to experiment with several of the vaccines under development in the world due to the high incidence of the disease in the country, the high circulation of the virus, its vast experience in mass vaccination programs and the great genetic diversity of its population, among other factors.
Currently, in the country, in addition to the vaccines developed by AstraZeneca-University of Oxford and Sinovac, those formulated by the multinational Johnson & Johnson and by the BioNTech consortium (Germany) and Wyeth / Pfizer (United States) are being tested.